Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-11-27
2007-11-27
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S178100, C424S277100, C435S069600, C530S387100
Reexamination Certificate
active
10631722
ABSTRACT:
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.
REFERENCES:
patent: 4036945 (1977-07-01), Haber
patent: 4331647 (1982-05-01), Goldenberg
patent: 4704692 (1987-11-01), Ladner
patent: 4824659 (1989-04-01), Hawthorne
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5011771 (1991-04-01), Bellet et al.
patent: 5057313 (1991-10-01), Shih et al.
patent: 5229275 (1993-07-01), Goroff
patent: 5443953 (1995-08-01), Hansen et al.
patent: 5567610 (1996-10-01), Borrebaeck et al.
patent: 5612016 (1997-03-01), Griffiths
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5716595 (1998-02-01), Goldenberg
patent: 5753206 (1998-05-01), McBride et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 6096289 (2000-08-01), Goldenberg
patent: 6254868 (2001-07-01), Leung et al.
patent: 6331175 (2001-12-01), Goldenberg
patent: 6761876 (2004-07-01), Serbedzija et al.
patent: 2002/0032315 (2002-03-01), Baca et al.
patent: WO 96/37516 (1996-11-01), None
patent: WO 98/44001 (1998-10-01), None
patent: WO 00/29584 (2000-05-01), None
patent: WO 00/63403 (2000-10-01), None
patent: WO 01/00245 (2001-01-01), None
patent: WO 0207783 (2002-01-01), None
Tsukada et al (Cancer Research 47, 4293-4295, Aug. 15th 1987).
Amato et al (J Cancer Res Clin Oncol, 2000, 126:161-167).
Laderoute and Pilarski. 1994. Anticancer Research 14:2429-2438.
Bergmann et al. 1987. Eur J Nuc Med 13:385-390.
Asano et al. 1998. Hybridoma vol. 17(2):185-190.
Takahashi et al. 1987. NCI Monogr 3:101-105.
Ishii et al. 1983. Annals New York Academy of Sciences pp. 270-276.
Tsukada et al. 1982. Proc. Natl. Acad. Sci. USA 79:7896-7899.
Goldenberg et al. 1987. Journal of Clinical Oncology 5(11):1827-1835.
Grimm et al. 2000. Gastroenterology 119:1104-1112.
Malamitsi et al. 1999. Anticancer Research 19:2201-2204.
William E. Paul, M.D. ed., Fundamental Immunology 242. 3d ed. 1993.
Dillman (J. Clinical Oncology. 1994. 12(7):1497-1515).
Ansel et al.,Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th Ed., Lea & Feibiger (1990).
Ausubel et al.,Current Protocols in Molecular Biology, John Wiley & Sons, New York (1987).
Baines et al., “Purification of Immunoglobulin G (IgG)”,Methods in Molecular Biology, vol. 10, pp. 79-104, The Humana Press, Inc. (1992).
Barbas et al.,Methods: A Companion to Methods in Enzymology, 2:119 (1991).
Barnes et al.,Cytotechnology, 32:109-123 (2000).
Bei et al.,J. Immunol. Methods, 186:245 (1995).
Bird et al., “Single Chain Antibody Variable Regions”,TIBTECH, vol. 9:132-137 (1991).
Caron et al.,J. Ex. Med., 176:1191-1195 (1991).
Carter et al.,Proc. Natl. Acad. Sci USA, 89:4285 (1992).
Co et al.,J. Immunol., 148:1149 (1992).
Coligan et al. (eds.),Current Protocols in Immunology, vol. 1, pp. 2.5.1-2.6.7; pp. 2.7.1-2.7.12; 2.8.1-2.8.10; 2.9.1.-2.9.3, and 2.10.4, John Wiley & Sons (1991).
Colman,Biochem. Soc. Symp., 63:141-147 (1998).
Coloma et al.,Nature Biotech, 15:159-163 (1997).
Courtenay-Luck, “Genetic Manipulation of Monoclonal Antibodies”,Monoclonal Antibodies: Production, Engineering, and Clinical Application, Cambridge University Press (1995), Ritter et al., eds., pp. 166-179.
Cragg et al.,Curr. Opin. Immunol., 11:541-547 (1999).
Edelman et al.,Methods in Enzymology, vol. 1, p. 422, Academic Press (1955).
Edelman et al.,Proc. Natl. Acad. Sci. USA, 63:78-85 (1969).
Fiedler et al.,Biotech., 13:1090-1093 (1995).
Fiedler et al.,Immunotechnology, 3:205-216 (1997).
Fitzgerald et al.,Protein Eng., 10(10):1221-1225 (1997).
Gennaro,Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co. (1990).
Gennaro,Remington's Pharmaceutical Sciences, 19th Ed., vol. I and II, Mack Publishing Co. (1995).
Gillies et al.,J. Immunol. Methods, 125:191 (1989).
Goldenberg,Ad. Exp. Med. Biol., 303:107-117 (1991).
Goldenberg et al.,Int. J. Oncol, 3:5-11 (1993).
Goldenberg et al.,Immunol. Today, 14:5-7 (1993).
Goldenberg,Am. J. Med., 94:297-312 (1993).
Goldenberg,CA-A Cancer J. for Clinicians, 44:43 (1994).
Goldenberg et al.,Immunol. Today, 16:261-264 (1995).
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th Ed., MacMillan Publishing Co. (1985).
Green et al.,Nature Genet., 7:13 (1994).
Greene et al.,Protective Groups in Organic Synthesis, John Wiley & Sons, New York (1999).
Hasan et al.,Prog. Clin. Biol. Res., 288:471 (1989).
Huse,Antibody Engineering: A Practical Guide, Boerrebaeck, ed., W.H. Freeman & Co., pp. 103-120 (1992).
Huse et al.,Science, 246:1274-1281 (1989).
Jackson et al.,Br. J. Cancer, 78:181-188 (1998).
Jaffers et al.,Transplantation, 41:572-578 (1986).
Johnson et al.,Current Opin. Struct. Biol., 3:5564-5571 (1993).
Jones et al.,Nature, 321:522 (1986).
Jori et al.,Photodynamic Therapy of Tumors and Other Diseases, Libreria Progetto (1985).
Kabat database, “Sequences of Proteins & Immunological Interest”, Bethesda, MD, U.S. Department of Health and Human Services, Public Health Service, NIH (1991).
Karacay et al.,Bioconjugate Chem., 11:842-854 (2000).
Kohler et al.,Nature, 256:495 (1975).
Larrick et al.,Methods: A Companion to Methods in Enzymology, 2:106 (1991).
Leung et al.,Hybridoma, 13:469-476 (1994).
Leung et al.,J. Immunol., 154:5919 (1995).
Leung et al.,Mol. Immunol., 32:1413-1427 (1995).
Lonberg et al.,Nature, 368:856 (1994).
Losman et al.,Cancer, 80:2660 (1997).
Losman et al.,Clin. Cancer Res., 5:3101 (1999).
Shawler et al.,J. Immunol., 135:1530-1535 (1985).
Sherwood et al.,Bio/Technology, 10:1446 (1992).
Shih et al.,Int. J. Cancer, 41:832 (1988).
Shih et al.,Int. J. Cancer, 46:1101 (1990).
Shopes,B.J. Immunol., 148:2918-2022 (1992).
Singer et al.,J. Immun., 150:2844 (1993).
Tatsuta et al.,Lasers Surg. Med., 9:422 (1989).
Taylor et al.,Int. Immun., 6:579 (1994).
Tempest et al.,Biotechnology, 9:266 (1991).
Tomizuka et al.,Nature Genetics, 16:133 (1997).
Uhlmann,Gene, 71:29 (1988).
Upeslacis et al., “Modification of Antibodies by Chemical Methods”,Monoclonal Antibodies: Principles and Applications, Birch et al., pp. 187-230, Wiley-Liss (1995).
Van den Bergh,Chem. Britain, 22:430 (1986).
Vaughan et al.,Nat. Biotechnol., 14:309-314 (1996).
Verhoeyen et al.,Science, 239:1534 (1988).
Ward et al., “Genetic Manipulation and Expression of Antibodies”,Monoclonal Antibodies: Principles and Applications, Wiley-Liss, Inc., Birch et al. (eds.), pp. 137-185 (1995).
Werner et al.,Arzneim.-Forsch./Drug Res., 48(II), NR. 8, 870-880 (1998).
Winter et al.,Ann. Rev. Immunol., 12:433 (1994).
Wong,Chemistry of Protein Conjugation and Cross-Linking, CRC Press (1991).
Wosnick et al.,Gene, 60:115 (1988).
Yang et al.,Appl. Environ. Microbiol., 64:2869-2874 (1998).
Yu et al.,Int. J. Cancer, 56:244 (1994).
Zhu et al.,Biotechnology, 14:192-196 (1996).
Mack et al.,Proc. Natl. Acad. Sci. USA, 92:7021-7025 (1995).
Mahiouz et al.,J. Immunol. Methods, 212:149-160 (1998).
McCafferty et al.,Nature, 348:552-553 (1990).
Mendez et al.,Nature Genetics, 15:146-156 (1997).
Mew et al.,J. Immunol., 130:1473 (1983).
Mew et al.,Cancer Res., 45:4380 (1985).
Miller,Ann. Rev. Microbiol., 42:177 (1988).
Nisonoff et al.,Arch. Biochem. Biophys., 89:230 (1960).
Orlandi et al.,Proc. Natl. Acad. Sci. USA, 86:3833 (1989).
Osbourn et al.,Immunotechnology, 2:181-196 (1996).
Oseroff et al.,Proc. Natl. Acad. Sci USA, 83:8744 (1986).
Oseroff et al.,Photochem. Photobiol., 46:83 (1987).
Pastan et al.,Cell, 47:641 (1986).
Pèlegrin et al.,Cancer, 67:2529 (1991).
Porter,Biochem. J., 73:119 (1959).
Price, “Production and Characterization of Synthetic Peptide-Derived Antibodies”,Monoclonal Antibodies: Production, Engineering, and Clinical Application, Ritter et al., eds., pp. 60-84, Cambridge University Press (1995).
Raag et al., “Singl
Goldenberg David M.
Hansen Hans J.
Qu Zhengxing
Faegre & Benson LLP
Helms Larry R.
Immunomedics Inc.
Tungaturthi Parithosh K.
LandOfFree
Alpha-fetoprotein Immu31 antibodies and fusion proteins and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-fetoprotein Immu31 antibodies and fusion proteins and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-fetoprotein Immu31 antibodies and fusion proteins and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3806219